WO2023079362 - PROCESSABLE COMPOSITIONS AND USE FOR THE SAME
National phase entry:
Publication Number
WO/2023/079362
Publication Date
11.05.2023
International Application No.
PCT/IB2022/000649
International Filing Date
02.11.2022
Title **
[English]
PROCESSABLE COMPOSITIONS AND USE FOR THE SAME
[French]
COMPOSITIONS APTES À ÊTRE TRAITÉES ET LEUR UTILISATION
Applicants **
RIPPLE THERAPEUTICS CORPORATION
Inventors
PARRAG, Ian, Charles
STATHAM, Matthew, Alexander John
BATTISTON, Kyle, Giovanni
NAIMARK, Wendy, Alison
DAY, Jonathan
BALDWIN, Emily
Priority Data
63/275,281
03.11.2021
US
63/275,283
03.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7847 | |
| EPO | Filing, Examination, Granting | 170097 | |
| Japan | Filing, Examination, Granting | 5125 | |
| South Korea | Filing, Examination, Granting | 10837 | |
| USA | Filing, Examination, Granting | 38590 |
Total:
232,496
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are compounds having the formula D1-L-D2, wherein D1 is a processable group, L is a linker, and D2 is a drug. Also described herein are pharmaceutical compositions comprising said compounds and methods for the treatment of ocular diseases or disorders including glaucoma, ocular hypertension, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration, post-cataract surgery and retinal vein occlusion.[French]
L'invention concerne des composés ayant la formule D1-L-D2, D1 étant un groupe apte à être traité, L un lieur et D2 un médicament. L'invention concerne également des compositions pharmaceutiques comprenant lesdits composés et des procédés pour le traitement de maladies ou de troubles oculaires comprenant le glaucome, l'hypertension oculaire, l'inflammation oculaire, l'œdème maculaire diabétique, l'inflammation postérieure, l'inflammation antérieure, la dégénérescence maculaire, la chirurgie post-cataracte et l'occlusion veineuse rétinienne.